This article is available to subscribers. Subscribe now. Already have an account? Sign in

CorrespondenceFree Preview

Long-Term MC4R Agonist Treatment in POMC-Deficient Patients

In this follow-up study involving two patients with POMC deficiency, treatment with the MC4R agonist setmelanotide resulted in a long-term reduction in body weight and BMI and induced satiety.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Peter Kühnen, M.D.
Charité–Universitätsmedizin Berlin, Berlin, Germany

Karine Clément, M.D., Ph.D.
Sorbonne Université, Paris, France

Funding and Disclosures

The investigator-initiated study was supported by a Berlin Institute of Health SPARK Berlin track 2 validation fund and by regulatory support from Rhythm Pharmaceuticals. Rhythm Pharmaceuticalssponsored the extension study. Support for patient follow-up was provided by the French Reference Center for Prader–Willi Syndrome (CRMR-Pradort).

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

Print Subscriber? Activate your online access.